Human Immunodeficiency Virus (HIV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
The human immunodeficiency virus (HIV) is a retrovirus belonging to the family of lentiviruses. Retroviruses can use their RNA and host DNA to make viral DNA and are known for their long incubation periods. Like other retroviruses, HIV infects the body, has a long incubation period (clinical latency), and ultimately causes the signs and symptoms of disease, here AIDS. HIV causes severe damage to the immune system and eventually destroys it by using the DNA of CD4+ cells to replicate itself. In that process, the virus eventually destroys the CD4+ cells.
·
In 2020, ~38,580 new HIV cases were being
diagnosed and reported in the USA, which suggests a decrease of overall ~8%
incidence cases in the country.
Thelansis’s “Human Immunodeficiency
Virus (HIV) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Human
Immunodeficiency Virus (HIV) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Human Immunodeficiency Virus (HIV) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Human Immunodeficiency Virus (HIV) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment